Monoclonal antibody TB94

Drug Profile

Monoclonal antibody TB94

Alternative Names: TB 94

Latest Information Update: 25 May 2007

Price : $50

At a glance

  • Originator Cancer ImmunoBiology
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Lung cancer

Most Recent Events

  • 08 Apr 2003 No development reported - Preclinical for Lung cancer in USA (Parenteral)
  • 27 Mar 2001 Preclinical development for Lung cancer in USA (Parenteral)
  • 02 Jul 1998 No-Development-Reported for Cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top